Tercica (original) (raw)
Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1. Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency, which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
| Property | Value |
|---|---|
| dbo:abstract | Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1. Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency, which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex conducted Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD. In 2007, a case between Insmed and Tercica was settled when the jury found that Insmed infringed patents licensed to Tercica for Increlex. In the settlement, Insmed agreed to stop selling Iplex in the United States as a treatment for growth deficiencies and to withdraw an application to have the drug approved for such use in Europe. In 2008, the Ipsen Group acquired Tercica and changed its name to Ipsen Biopharmaceuticals, Inc. (en) |
| dbo:country | dbr:United_States |
| dbo:fate | Acquired byIpsen Group (en) |
| dbo:industry | dbr:Health_care |
| dbo:locationCity | dbr:Brisbane,_California |
| dbo:wikiPageExternalLink | http://www.ipsenus.com/ |
| dbo:wikiPageID | 5385283 (xsd:integer) |
| dbo:wikiPageLength | 2610 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1106781957 (xsd:integer) |
| dbo:wikiPageWikiLink | dbc:Brisbane,_California dbc:Biotechnology_companies_of_the_United_States dbr:Genentech dbr:Brisbane,_California dbr:Ipsen dbr:Food_and_Drug_Administration dbc:Companies_formerly_listed_on_the_Nasdaq dbr:Health_care dbr:Laron_syndrome dbc:Companies_based_in_San_Mateo_County,_California dbr:IGF-1 dbr:Increlex dbr:Human_growth_hormone dbr:Primary_IGFD dbr:RhIGF-1 |
| dbp:fate | Acquired by Ipsen Group (en) |
| dbp:hqLocationCity | dbr:Brisbane,_California |
| dbp:hqLocationCountry | United States (en) |
| dbp:industry | dbr:Health_care |
| dbp:name | Tercica, Inc. (en) |
| dbp:successor | Ipsen Biopharmaceuticals, Inc. (en) |
| dbp:wikiPageUsesTemplate | dbt:Citation_needed dbt:End_date dbt:Infobox_company dbt:One_source dbt:Portal dbt:Refimprove dbt:US-corp-stub dbt:Med-company-stub dbt:Biotech-stub |
| dct:subject | dbc:Brisbane,_California dbc:Biotechnology_companies_of_the_United_States dbc:Companies_formerly_listed_on_the_Nasdaq dbc:Companies_based_in_San_Mateo_County,_California |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatBiotechnologyCompaniesOfTheUnitedStates yago:WikicatCompaniesBasedInSanMateoCounty,California yago:Abstraction100002137 yago:Company108058098 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 |
| rdfs:comment | Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1. Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency, which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. (en) |
| rdfs:label | Tercica (en) |
| owl:sameAs | freebase:Tercica yago-res:Tercica wikidata:Tercica https://global.dbpedia.org/id/4vCeF |
| prov:wasDerivedFrom | wikipedia-en:Tercica?oldid=1106781957&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Tercica |
| foaf:name | Tercica, Inc. (en) |
| is dbo:wikiPageWikiLink of | dbr:Brisbane,_California dbr:Laron_syndrome dbr:Rho_Capital_Partners |
| is foaf:primaryTopic of | wikipedia-en:Tercica |